ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo ...

Understanding Isotopes and Targets Key in Radiopharmaceutical Therapy - Jessica Jensen ...

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a proffered paper session for prostate ...

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session on future therapy targets ...

Prostate cancer (PCa) is the leading cause of cancer‑related death among men worldwide. PCa often develops resistance to standard androgen deprivation therapy and androgen receptor (AR) pathway ...

There were 137 patients included in this study with a median age of 71.8 years (range 50.1-92.8). There were 77.4% of patients that presented de novo stage IV, 16.1% with visceral metastasis, and 53.3 ...

Pembrolizumab is established as adjuvant therapy for patients with high-risk clear cell renal cell carcinoma (ccRCC) after resection. Patients with completely resected metastatic disease (M1 NED) seem ...

Penile squamous cell carcinoma (PSCC) is becoming increasingly common and posing a severe threat to men's health, particularly in developing countries. The function of long non-coding RNAs (lncRNAs) ...

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a proffered paper session for prostate cancer. Dr. Rana McKay delivered the ...

(UroToday.com) The 2024 ESMO annual meeting included a session on radioligand theranostics in prostate cancer, featuring a presentation by Dr. Ken Herrmann discussing the status quo and new ...

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the session Biochemical failure post-local therapy: An opportunity for tailored ...